Exact Sciences Corp

EXAS

Company Profile

  • Business description

    Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

  • Contact

    5505 Endeavor Lane
    MadisonWI53719
    USA

    T: +1 608 284-5700

    E: [email protected]

    https://www.exactsciences.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2025

    Employees

    7,000

Exact Sciences Corp News & Analysis

etfs

ARK Innovation ETF has likely been a disappointment for most investors

Investors are fleeing for the exits amid the fund's underperformance this year.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,966.703.200.04%
CAC 407,857.3656.480.72%
DAX 4024,217.37247.011.03%
Dow JONES (US)44,632.99204.57-0.46%
FTSE 1009,136.3254.880.60%
HKSE25,524.4537.68-0.15%
NASDAQ21,098.2980.29-0.38%
Nikkei 22540,674.55323.72-0.79%
NZX 50 Index12,914.5621.85-0.17%
S&P 5006,370.8618.91-0.30%
S&P/ASX 2008,704.606.900.08%
SSE Composite Index3,609.7111.770.33%

Market Movers